REMEGEN
- Country
- 🇭🇰Hong Kong, China
- Ownership
- Public
- Established
- 2008-07-04
- Employees
- 3.4K
- Market Cap
- -
- Website
- http://www.remegen.com
- Introduction
The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., headed by Mr. Wang Weidong, and American scientist Dr. Fang Jianmin. The company is committed to discovering, developing, producing and commercializing first-of-its-kind, best-in-class biopharmaceuticals, and creating a number of new biological drugs with significant clinical va...
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05867303
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
🇦🇺Southern Oncology Clinical Research Unit, Bedford Park, South Australia, Australia
RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 106
- Registration Number
- NCT05821933
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 82
- Registration Number
- NCT05804526
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
A Study of Telitacicept in Patients With Primary IgA Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 308
- Registration Number
- NCT05799287
- Locations
- 🇨🇳
Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Peking University Shougang Hospital, Beijing, Beijing, China
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
- Conditions
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT05745740
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Study of Telitacicept in Generalized Myasthenia Gravis
- Conditions
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05737160
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
🇨🇳The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Henan Provincial People's Hospital, Zhengzhou, Henan, China
Efficacy and Safety of RC28-E Versus Aflibercept
- Conditions
- Interventions
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 432
- Registration Number
- NCT05727397
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05687526
- Locations
- 🇨🇳
Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Chengdu Women's & Children's Central Hospital, Chengdu, Sichuan, China
A Study of Telitacicept in Lupus Nephritis
- Conditions
- Interventions
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05680480
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳Affiliated Hospital of Hebei University, Baoding, Hebei, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome
- Conditions
- Interventions
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 375
- Registration Number
- NCT05673993
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China